IMPACt Trial: MammaPrint and BluePrint Molecular Subtyping Guide Treatment Decisions in Breast Cancer

Reshma Mahtani; H. Soliman; E. Rehmus; V. Shah; G. Srkalovic; E. Levine; B. Mavromatis

IMPACt Trial: MammaPrint and BluePrint Molecular Subtyping Guide Treatment Decisions in Breast Cancer

Reshma Mahtani, H. Soliman, E. Rehmus, V. Shah, G. Srkalovic, E. Levine, B. Mavromatis

Miami Cancer Institute

Research output: Contribution to journal › Article › peer-review

Original language	American English
Journal	Cancer Research / San Antonio Breast Cancer Symposium 2017
Volume	78
State	Published - Feb 15 2018

Disciplines

Medicine and Health Sciences

Cite this

@article{c5040828e0374b9f95fa84416f2be793,

title = "IMPACt Trial: MammaPrint and BluePrint Molecular Subtyping Guide Treatment Decisions in Breast Cancer",

author = "Reshma Mahtani and H. Soliman and E. Rehmus and V. Shah and G. Srkalovic and E. Levine and B. Mavromatis",

note = "Abstract. Background: IMPACt is a prospective, case-only study to measure the effect of MammaPrint (MP) and BluePrint (BP) on treatment decisions in breast cancer patients. Here, we report the results of the primary objective in women aged ≥18 years with histologically proven invasive stage I-II, hormone receptor (HR) positive, and HER2-negative breast cancer.",

year = "2018",

month = feb,

day = "15",

language = "American English",

volume = "78",

journal = "Cancer Research / San Antonio Breast Cancer Symposium 2017",

}

TY - JOUR

T1 - IMPACt Trial: MammaPrint and BluePrint Molecular Subtyping Guide Treatment Decisions in Breast Cancer

AU - Mahtani, Reshma

AU - Soliman, H.

AU - Rehmus, E.

AU - Shah, V.

AU - Srkalovic, G.

AU - Levine, E.

AU - Mavromatis, B.

N1 - Abstract. Background: IMPACt is a prospective, case-only study to measure the effect of MammaPrint (MP) and BluePrint (BP) on treatment decisions in breast cancer patients. Here, we report the results of the primary objective in women aged ≥18 years with histologically proven invasive stage I-II, hormone receptor (HR) positive, and HER2-negative breast cancer.

PY - 2018/2/15

Y1 - 2018/2/15

UR - https://aacrjournals.org/cancerres/article/78/4_Supplement/P6-13-04/632830/Abstract-P6-13-04-IMPACt-trial-MammaPrint-and

M3 - Article

VL - 78

JO - Cancer Research / San Antonio Breast Cancer Symposium 2017

JF - Cancer Research / San Antonio Breast Cancer Symposium 2017

ER -

IMPACt Trial: MammaPrint and BluePrint Molecular Subtyping Guide Treatment Decisions in Breast Cancer

Disciplines

Other files and links

Cite this